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Objectives 
The aim of this study was to investigate the utility of a comprehensive imaging protocol 
including echocardiography and cardiovascular magnetic resonance (CMR) in the 
diagnosis and differentiation of hypertensive heart disease and heart failure with 
preserved ejection fraction (HFpEF). 
Background 
Hypertension is present in up to 90% of patients with HFpEF and is a major etiological 
component. Despite current recommendations and diagnostic criteria for HFpEF, no 
non-invasive imaging technique has as yet shown the ability to identify any structural 
differences between patients with hypertensive heart disease and HFpEF. 
Methods 
We conducted a prospective cross-sectional study of 112 well-characterised patients 
(62 with HFpEF, 22 with hypertension and 28 healthy controls). All patients underwent 
cardiopulmonary exercise and biomarker testing and an imaging protocol including 
echocardiography with speckle tracking analysis and CMR including T1 mapping pre- 
and post-contrast. 
Results 
Echocardiographic global longitudinal strain (GLS) and extracellular volume (ECV) 
measured by CMR were the only variables able to independently stratify between the 
three groups of patients. ECV was the best technique for differentiation between 
hypertensive heart disease and HFpEF (ECV AUC 0.88; GLS AUC 0.78, p<0.001 for 
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both). Using ECV, an optimal cut-off of 31.2% gave 100% sensitivity and 75% 
specificity. ECV was significantly higher and GLS was significantly reduced in subjects 
with reduced exercise capacity (lower peak VO2 and higher VE/VCO2) (p<0.001 for both 
ECV and GLS). 
Conclusions 
Both GLS and ECV are able to independently discriminate between hypertensive heart 
disease and HFpEF and identify patients with prognostically significant functional 
limitation. ECV is the best diagnostic discriminatory marker of HFpEF and could be 
used as a surrogate end-point for therapeutic studies. 
CONDENSED ABSTRACT 
Hypertension is the commonest etiological condition in patients with HFpEF. 
Development of a non-invasive technique to differentiate between healthy controls, 
hypertensive and HFpEF patients has yet to be developed. We evaluated 62 HFpEF 
patients, 22 hypertensive patients and 28 healthy controls with a comprehensive 
imaging protocol including echocardiographic speckle tracking and CMR T1 mapping. 
We found that extracellular volume measured by CMR T1 mapping was the best 
differentiator between the three groups. Both global longitudinal strain and ECV hold 
promise as a non-invasive marker in HFpEF that may help guide management. 
 
Keywords: heart failure; HFpEF; hypertension; cardiovascular magnetic resonance 
imaging; speckle-tracking; T1 mapping  
5 
 
Heart failure with preserved ejection fraction (HFpEF) represents 40-50% of all cases of 
heart failure (HF) and is associated with significant morbidity and mortality.(1) Several 
randomized control trials have been conducted in search for a useful therapy for HFpEF 
without success and therefore unfortunately mortality in patients with HFpEF has 
remained unchanged over the past 20 years.(2) With hindsight, it has become more 
accepted that the correct identification and selection of HFpEF patients was a major 
contributing factor to this inability to demonstrate lack of therapeutic benefit.  
Initially, HFpEF was simplistically assigned to impaired myocardial relaxation (diastolic 
dysfunction) but it is now recognised that there are structural and functional changes 
that occur in this condition.(3) These include changes in both the myocyte (such as 
changes in titin)(4) and the extracellular matrix (e.g. increased inflammation and 
fibrosis) and even subclinical left ventricular systolic dysfunction.(5,6) In this work we 
hypothesized that advanced imaging techniques such as speckle tracking 
echocardiography and cardiovascular magnetic resonance (CMR) would allow clearer 
identification of HFpEF cohorts.(6,7) 
HFpEF is associated with many comorbidities, including systolic hypertension which is 
apparent in up to 80-90% of HFpEF patients.(8) Chronic hypertension is also associated 
with subclinical changes in myocardial structure and function, including in the 
extracellular matrix.(9) It is conceivable that changes seen in chronic hypertension are a 
precursor to HFpEF, therefore it is paramount to be able to non-invasively identify the 
threshold that separates hypertensive heart disease and HFpEF, allowing for precise 
disease phenotyping and targeting of treatment. This is particularly important as the 
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standard echocardiographic criteria used for diagnosis in HFpEF(10) are often found in 
patients with hypertensive heart disease.(11) 
To the best of our knowledge, no study has previously used a comprehensive multi-
parametric imaging protocol to investigate patients with HFpEF and hypertension in 
such detail. The aim of this study was to use speckle-tracking echocardiography and a 
comprehensive CMR protocol including T1 mapping and tagging to fully characterise 
resting myocardial structural and functional changes in patients with cardiopulmonary 
exercise testing (CPEX)-demonstrated HFpEF compared to patients with asymptomatic 
hypertension and to healthy controls. 
METHODS 
Patient Selection 
Three groups were studied: 1. HFpEF patients were identified via a large screening 
programme for HFpEF conducted in primary care. They were diagnosed on the basis of 
symptoms and signs consistent with HF, elevated BNP at the time of diagnosis (>35 
pg/mL), normal left ventricular dimensions with ejection fraction (LVEF) >50%(12) plus 
evidence of echocardiographic abnormalities such as left ventricular hypertrophy (LVH), 
left atrial enlargement, or evidence of diastolic dysfunction as per the 2016 European 
Society of Cardiology guidelines.(12) Determination of diastolic dysfunction required at 
least 2 of the following to be present: E/e’ >13, mean septal and lateral e’ velocity 
<9cm/s or LA volume index >34ml/m2.  Finally, all patients underwent CPEX in order to 
confirm the presence of exercise limitation of cardiac etiology by peak VO2<80% 
predicted and VE/VCO2 slope>32.(13) All patients underwent a symptom-limited 
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protocol and were only included in the study if they were able to achieve a respiratory 
exchange ratio (RER) of ≥1. We excluded any patients with an underlying 
cardiomyopathy (such as hypertrophic cardiomyopathy, amyloid or ischemic 
cardiomyopathy). Significant underlying ischemia was excluded by a combination of 
clinical history and either non-invasive ischemia testing or invasive coronary 
angiography if indicated. Additionally, any patient with late gadolinium enhancement on 
CMR consistent with prior myocardial infarction was excluded. We excluded people with 
predominant lung disease such as chronic obstructive pulmonary disease (COPD) or 
pulmonary fibrosis (with an FEV1<1.5) and patients with anemia (hemoglobin <110g/L). 
2. Non-consecutive patients with a history of chronic arterial hypertension were 
recruited from the Aberdeen Royal Infirmary hypertension database. Patients were 
required to have a documented history of essential hypertension (systolic BP 
>140mmHg) for greater than 6 months and to be on at least one treatment agent. We 
excluded any patients with overt cardiac disease (such as prior myocardial infarction or 
any valve disease classified as worse than mild) and any patient with secondary 
hypertension. All hypertensive patients were self-declared asymptomatic at the time of 
evaluation. Patients were required to have no previous documented cardiovascular 
disease other than hypertension. To match for co-morbidity distribution between groups, 
we excluded patients with significant underlying pulmonary disease and anemia. 3. 
Healthy volunteers were recruited from public advertising. Volunteers had no self-
declared past medical history and were not taking any medication at the time of 
recruitment. Additionally, we performed a case record review to ensure there was no 
significant past medical history, a resting ECG, echocardiogram and BNP. Volunteers 
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were only recruited if all of these were normal. The study was approved by the North of 
Scotland research ethics committee and all subjects provided informed consent. 
Imaging Protocol 
Echocardiography: All patients underwent a comprehensive 2-dimensional 
echocardiographic protocol using a Vingmed E9 system (GE Healthcare, Norway) with 
a 2.5-MHz probe. Standard views were taken in the parasternal, apical and subcostal 
windows.  
Cardiovascular Magnetic Resonance (CMR): All patients then underwent a full CMR 
protocol on a 3 Tesla (Achieva, Phillips, The Netherlands). The full CMR protocol has 
been described previously.(14,15) Briefly, following localizers, cine images were 
acquired in 2, 3 and 4-chamber views, and a full left ventricular short-axis stack taken. 
Following this, a native T1 mapping sequence was performed using a modified Look 
Locker Inversion recovery sequence (MOLLI, 3(3)3(3)5 scheme) in 2 short-axis slices 
corresponding to mid-ventricular level. Then, tagged magnetic resonance imaging 
sequences were performed in short axis at the base, mid-cavity and apical levels. 
Gadolinium contrast was given and late gadolinium enhancement (LGE) imaging 
performed in the full short-axis stack and the 3 long-axis views. Finally, 2 post-contrast 
MOLLI (5(3)) slices were performed at exactly 15 minutes post-contrast at the same 
mid-cavity level. A blood sample was taken at the time of CMR scanning for 
measurement of haematocrit. 
Image Analysis 
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Both echocardiographic and CMR images were each analysed independently by 2 
experienced operators. Echo images were analysed offline using EchoPac (GE 
Healthcare, Norway). CMR images were analysed offline using CVI42 (Circle 
Cardiovascular Imaging, Calgary, Canada) for assessment of left ventricular mass, 
volumes, T1 mapping and LGE. Tagged CMR images was analysed using HARP 
(Diagnosoft, Palo Alto, California). Extracellular volume as a percentage of the 
myocardium (ECV) was calculated using the formula ECV = (1−hematocrit) × 
(ΔR1myocardium/Δ R1blood), where R1 = 1/T1.  
Statistical Analysis 
Statistical analysis was performed using SPSS v.22.0 (IBM, Armonk, NY, USA). 
Continuous data are reported as mean ± standard deviation while categorical data are 
reported as number with percentage in brackets. Comparisons between the three 
groups were made using a one-way ANOVA with an independent t-test with post-hoc 
Bonferroni correction for between group comparisons for continuous variables with 
normal distribution, Kruskal-Wallis test for non-normally distributed continuous variables 
and a chi-square test for categorical variables. Correlations were assessed using 
Pearson’s (for parametric data) or Spearman’s (for non-parametric data) correlation. 
Optimal cut-offs for significant variables of interest were calculated using Youden’s 
index (sensitivity + (1-specificity)). Receiver-operator characteristic curves were then 
plotted using the optimal cut-off in order to assess the area under the curve. Logistic 
regression analysis was performed to determine the relationship between significant 
echocardiographic and CMR variables and the diagnosis of HFpEF. Statistical 
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significance was indicated by p<0.05. Both intra- and inter-observer variabilities were 
calculated as mean ± SD between 2 independently measured variables. 
RESULTS 
Baseline Characteristics 
In total we included 112 patients; 62 with HFpEF, 22 with hypertension and 28 healthy 
controls. Baseline characteristics are shown in Table 1. There was no significant 
difference in age between the three groups however there were more male 
hypertensive patients. 18 of the hypertensive patients (82%) were taking at least 2 anti-
hypertensive medications, however no patients in this study were taking 
mineralocorticoid receptor antagonists. HFpEF patients were overweight compared to 
the other two groups and had significantly higher BNP levels than both hypertensive 
patients and healthy controls. There were significant differences in CPEX parameters 
with HFpEF patients demonstrating significant cardiac limitation on exercise compared 
to both hypertensive patients and controls – HFpEF patients had a significantly lower 
VO2 and higher VE/VCO2 compared to hypertensive patients and controls (both 
p<0.001). HFpEF patients had a significantly lower heart rate at peak exercise 
compared to hypertensive patients and controls.(16) No CPEX tests were terminated 
early due to blood pressure response. 
Echocardiographic Parameters 
Echocardiographic data are summarised in Table 2. There were no significant 
differences between groups in LVEF, transmitral velocities or E/E’. HFpEF patients had 
significantly lower eGLS than both hypertensive patients (p=0.004) and controls 
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(p<0.001) but similar eGCS to hypertensive patients. Controls had significantly higher 
eGCS than both HFpEF patients (p<0.001) and hypertensive patients (p=0.002). Left 
ventricular torsion was significantly reduced in both HFpEF patients and hypertensive 
patients compared to controls (p<0.001 for both groups) but there was no significant 
difference between the two patients groups. Global circumferential systolic strain rate 
was significantly lower in hypertensive patients compared to controls (p=0.019). 
Reproducibility of echocardiographic speckle tracking was as follows: (global 
longitudinal strain (GLS): inter-observer 5±2% intra-observer: 4±2%; global 
circumferential strain (GCS) both inter- and intra-observer variability were 4±1%).   
Cardiovascular Magnetic Resonance Parameters 
CMR data are summarised in Table 3. There were no significant differences in indexed 
LV volumes or LVEF between all 3 groups. None of the patients had late gadolinium 
enhancement present. Hypertensive patients had a significantly higher indexed LV 
mass compared to both HFpEF patients (p<0.001) and controls (p<0.001). Controls also 
had significantly lower indexed LV mass than HFpEF patients (p<0.001). HFpEF 
patients had a significantly lower GCS measured by CMR (cGCS) compared to controls 
(p=0.039). HFpEF patients had a trend towards a higher native T1 than both 
hypertensive patients and controls. ECV was significantly higher in both HFpEF patients 
(35.9% ± 5.0) and hypertensive patients (31.9% ± 5.2) versus controls (27.0% ± 4.3; 
p<0.001 and p=0.04 respectively). ECV was also significantly higher in HFpEF patients 
vs. hypertensives (p=0.04). Representative examples of the speckle tracking and T1 
mapping analysis are shown in Figure 1. Our inter- and intra-observer variability for all 
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T1 mapping analysis were 2.7±1.5% and 1.5±0.5%. Reproducibility for CMR tagging 
has been previously reported.(14) 
Differentiation Between HFpEF, Hypertension and Controls 
eGLS and CMR-derived ECV were the only 2 parameters that were significantly 
different between HFpEF and hypertensive patients. Both were independently 
associated with the diagnosis of HFpEF (GLS: OR 1.50; 95% CI 1.08-2.08, p=0.016; 
ECV: OR 1.21; 95% CI 1.02-1.42, p=0.025). Using ROC analysis, ECV was an excellent 
discriminator between HFpEF and hypertension (AUC: 0.88; 95% CI 0.70-1.00, 
p=0.005) while eGLS was also a good discriminator between the two patient groups 
(AUC: 0.78; 95% CI 0.57-0.99, p=0.037). The optimal cut-off for differentiation between 
HFpEF and hypertension using ECV was 31.2% which gave a sensitivity of 100% and 
specificity of 75%. The optimal cut-off using GLS was -17.8% which gave a sensitivity of 
83.3% and a specificity of 62.5% (Figure 2). In a multivariable analysis with these two 
variables, only ECV remained significantly associated with a diagnosis of HFpEF (GLS: 
OR 2.68 per 1% increase in GLS; 95% CI 0.86-8.34, p=0.09; ECV: OR 1.99 per 1% 
increase in ECV; 95% CI 1.06-3.72, p=0.032). 
ECV, torsion and eGCS were able to differentiate between hypertensive patients and 
controls. All 3 variables were significantly correlated (p <0.01) and were associated with 
diagnosis of hypertensive heart disease (ECV: OR 1.31; 95% CI 1.02-1.69, p=0.038; LV 
torsion: OR 0.54; 95% CI 0.34-0.86, p=0.01; GCS: OR 1.47; 95% CI 1.11-1.95, 
p=0.007) however in multivariable stepwise analysis none of these variables remained 
significant. 
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Correlation of ECV and GLS with Structural and Functional Parameters 
As the best novel parameters identified, differences in ECV and GLS were examined 
based on the severity of structural and functional characteristics of patients. There was 
a strong correlation between GLS and peak VO2 (r=-0.54, p=0.002) and GLS and 
VE/VCO2 (r=0.47, p<0.001), however there were no significant correlations between 
GLS and BNP (r=-0.004, p=0.98) or E/E’ (r=0.10, p=0.46). There were significant 
correlations between ECV and peak VO2 (r=-0.41, p=0.001), VE/VCO2 (r=0.28, 
p=0.024) and BNP (r=0.32, p=0.026). There was no correlation between ECV and E/E’ 
(r=-0.008, p=0.95). 
There were significant differences in ECV and GLS in patients with more severe 
functional limitation on CPEX. Patients with peak VO2 less than the median (17.5 
ml/kg/min) had significantly higher ECV and GLS than those with VO2 greater than the 
median (ECV: 35.9% vs 30.5%, p<0.001; GLS: -16.18% vs. -19.08%, p<0.001). 
Patients with VE/VCO2 greater than the median (34.06) had significantly higher ECV 
and GLS than those with VE/VCO2 less than the median (ECV: 35.6% vs 30.5%, 
p<0.001; GLS: -16.05% vs. -19.15%, p<0.001). There was no significant difference in 
ECV or GLS based on E/E’ or median BNP (Figure 3). 
DISCUSSION 
In this study we identified several important findings. First, an advanced imaging 
protocol including echocardiographic speckle tracking and T1 mapping can differentiate 
between patients with comprehensively CPEX-characterised HFpEF, hypertensive heart 
disease and controls. Both hypertensive heart disease and HFpEF are associated with 
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a reduction in LV torsion and in eGCS. Additionally, both GLS and ECV are able to 
completely separate the 3 phenotypes (HFpEF, hypertensive heart disease and normal) 
and ECV is the strongest imaging diagnostic marker for independently differentiating 
between hypertensive heart disease and HFpEF. Finally, we have also showed, for the 
first time that both GLS and ECV correlate strongly and are significantly different in 
patients with objective functional limitation based on peak VO2 and VE/VCO2, which are 
established markers of prognosis in HFpEF.  
The diagnosis of HFpEF remains challenging. Although echocardiographic criteria(12) 
are clear, these abnormalities are often found in hypertensive patients without HFpEF. 
Additionally, although CPEX is an extremely valuable diagnostic tool for identifying 
those who are limited on exercise, a majority of patients with HFpEF are unable to 
exercise, hence, a further technique to clarify the diagnosis would be desirable.  
Echocardiographic determination of diastolic dysfunction is primarily via the use of 
tissue Doppler imaging, particularly the E/E’ ratio, however this is not completely reliable 
as it can still be normal in patients with HF, and conversely, be abnormal in 
hypertensive heart disease.(11,17) Recently, speckle-tracking echocardiography has 
been used to identify subclinical LV dysfunction with HFpEF patients being shown to 
have reduced GLS.(6) Additionally, reduced GLS has also been shown to be an 
independent marker of adverse prognosis in patients with HFpEF.(18) Our findings are 
in keeping with those of the PARAMOUNT echocardiographic substudy, which showed 
that reduced GLS was also present in HFpEF patients compared to both controls and 
hypertensive patients.(6) Underlining the importance of subclinical LV dysfunction in the 
pathophysiology of HFpEF, a further recent study by Kosmala et al. also showed that 
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subclinical systolic dysfunction measured by reduced GLS was the best discriminator 
between HFpEF patients with exercise limitation and those without.(19)  
In our comprehensive imaging study, we have also shown that while both ECV and 
echocardiographic GLS are able to identify HFpEF patients, ECV measured non-
invasively by T1 mapping is the best technique for independently differentiating between 
HFpEF and hypertensive patients. In our study, the presence of an ECV greater than 
31.2% had 100% sensitivity for diagnosis of HFpEF.  This highlights the potential 
diagnostic utility of ECV in HFpEF patients. We speculate that an increase in ECV is 
one of the earliest pathophysiological changes seen in both HFpEF and hypertension, 
and that as the progression from hypertensive heart disease to HFpEF is perhaps 
reflected (or caused) by the increase in ECV. In our study we also measured ECV in our 
control group, confirming the normalcy limits. We postulate that this increase in ECV 
reflects underlying changes such as fibrosis, collagen expansion and increased 
collagen cross-linking that lead to alterations in myocardial function.(5)  Our findings are 
also in keeping with the recent study by Rommel et al. in which the authors evaluated 
24 patients with HFpEF, finding that these patients had a significantly higher ECV than 
controls and that ECV was correlated with invasive measures of ventricular 
stiffness.(22) 
We also identified that GCS and LV torsion were all significantly different in controls 
compared to both patient groups.  When present, fibrosis in hypertension particularly 
seems to involve the myocardial midwall which contains circumferential shortening 
fibres and might lead to GCS being affected before longitudinal shortening.(23) The fact 
that GCS is reduced in both hypertensive patients and in HFpEF whereas only GLS is 
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reduced in HFPEF might reflect the underlying disease process, and might explain why 
GLS seems to be a more powerful predictor of prognosis in both hypertension and 
HFpEF than GCS.(18,24) As the circumferential fibres also contribute to LV torsion, it 
therefore follows that LV torsion is reduced in HFpEF and hypertension.  
The utility of left ventricular torsion as a diagnostic marker in HFpEF is not clear – this is 
in contrast to HFrEF where LV torsion is almost always decreased.(25) In contrast, 
studies in HFpEF have had conflicting results. Similar to our study, Yip et al. found that 
LV torsion was significantly reduced in both HFpEF and HFrEF patients compared to 
controls.(26) This replicated results from a study by Tan et al, who also found that as 
well as a reduction in GLS in HFpEF patients compared to controls, there was also a 
significant reduction in LV torsion in HFpEF patients.(27) A recent analysis in the MESA 
study found that increased mass at baseline (often associated with hypertension) was 
associated with a reduction in torsion, although there was an increase in torsion noted 
in patients with progressive age-related left ventricular remodelling in a further study 
from this group, suggesting that the relationship is still unclear.(28,29)  
These findings could have important clinical diagnostic and therapeutic implications. 
While undoubtedly echocardiography remains the mainstay of diagnosis and 
management of HF patients, where available, CMR could become an important tool for 
further characterisation of patients, particularly in difficult clinical cases. If ECV also 
proves to be a non-invasive marker of disease activity, this could help investigation of 
novel therapeutic options.  
Both peak VO2 and VE/VCO2 are established markers of functional limitation and 
prognosis in HFpEF.(30) We found that both GLS and ECV were correlated with 
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functional limitation as measured using CPEX. This perhaps supports our hypothesis 
that the development of subclinical dysfunction measured by GLS and the development 
of structural changes shown by an increase in ECV are precursors to the development 
of clinical HF. Recent work has suggested that GLS does correlate well with exercise 
capacity in HFpEF,(31) and we have added to this by showing a similar relation with 
ECV measured by T1 mapping. While both speckle-tracking echocardiography and 
CMR T1 mapping are not yet routine in general clinical practice, we believe that our 
study, in line with others, has clearly demonstrated the utility of these techniques in 
diagnosing HFpEF in a more reliable manner than previously available. 
Study Limitations 
Our study has some limitations. First, it was a single-centre study with relatively small 
numbers, although it is still one of the largest studies in the area. Additionally, we 
performed a comprehensive characterisation of patients with CPEX, echocardiography 
and CMR. Second, post-contrast T1 mapping was performed only at one time point (15 
minutes). The optimal time-point has yet to be confirmed. Third, we did not perform 
exercise echocardiography, which might provide some further differentiation in HFpEF 
patients.(19) Fourth, we were unfortunately unable to completely match the cohorts for 
gender due to the inability to recruit enough female participants, a well-recognized 
shortfall with many studies. In addition, although we excluded significant underlying 
coronary artery disease where clinically indicated and excluded patients with an 
ischemic pattern of LGE on CMR or exercise-induced ischaemia, as we did not perform 
invasive coronary angiography we accept that the presence of any subclinical CAD may 
have affected the results. Finally, as the patients studied were not recruited from a 
18 
 
single presenting group, it is possible that the diagnostic performance of ECV and GLS 
may differ in other groups of patients, hence these techniques should be validated in 
other cohorts. 
CONCLUSIONS 
Using a comprehensive imaging protocol including echocardiography and CMR, both 
speckle tracking and T1 mapping were able to identify underlying myocardial structural 
differences and differentiate between functionally-limited HFpEF patients, those with 
hypertensive heart disease and healthy controls. ECV measured by CMR T1 mapping 
was the best independent predictor of the diagnosis of HFpEF, with an optimal cut-off of 
ECV greater than 31.2% having 100% specificity and 75% sensitivity. ECV could be 
considered the first non-invasive imaging biomarker of HFpEF, providing improved 
diagnostic clarity and potentially serving as a surrogate end-point in clinical trials. 
 
  
19 
 
PERSPECTIVES 
Competency in Medical Knowledge 
Differentiation of HFpEF, hypertensive heart disease and healthy subjects can be 
difficult using current non-invasive imaging techniques. T1 mapping using CMR can be 
used to specifically identify each of the three groups of patients with its assessment of 
extracellular volume. 
Translational Outlook 
ECV measured by T1 mapping could be used as both a therapeutic and prognostic 
marker in HFpEF and could potentially be used to predict which patients with 
hypertensive heart disease are at higher risk of developing heart failure.  
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Figure Legend 
1. Representative examples. 
Representative examples of echocardiographic global longitudinal strain (eGLS) 
(top row - ED – end-diastole; ES – end-systole) and pre- and post-contrast T1 
mapping (middle and bottom rows respectively). Column A shows a male healthy 
volunteer with an eGLS of -22.1%. Mean native T1 was 1212.7ms, post-contrast 
T1 was 586.1ms. ECV was calculated at 24.9%. Column B shows a hypertensive 
male with an eGLS of -18.2%. Mean native T1 was 1169.0ms, post-contrast T1 
was 593.5ms. ECV was calculated at 31.2%. Column C shows a male with 
HFpEF (LVEF with an eGLS of -15.0%. Mean native T1 was 1265.0ms, post-
contrast T1 was 484.8ms. ECV was calculated at 36.3%. 
2. ROC Curves. 
Sensitivity and specificity for differentiation of HFpEF and hypertensive patients. 
ECV (blue) gave an area under the curve of 0.88 (95% CI 0.70-1.00, p=0.005) 
while eGLS (red) gave an area under the curve of 0.78 (95% CI 0.57-0.99, 
p=0.037). 
3. ECV and GLS Compared to Structural and Functional Parameters. 
The relationship between structural and functional parameters compared to ECV 
(left) and GLS (right). Patients with functional limitation measured by CPEX (peak 
VO2 less than the median and VE/VCO2 greater than the median) had 
significantly increased ECV and reduced GLS. Data is shown as mean ± SD. 
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Figure 1. 
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Figure 2.  
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Figure 3.  
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Table 1. Baseline Characteristics 
 HFpEF 
(n=62) 
Hypertensives 
(n=22) 
Controls (n=28) 
Age 70.8 ± 7.6 66.9 ± 5.2 67.7 ± 11.2 
Male 20 (32.3) 17 (77.2) 14 (50.0) 
BMI (kg/m2) 29.2 ± 3.5* 26.7 ± 2.9 25.6 ± 2.7 
Hypertension 47 (75.8) 22 (100) 0 (0) 
Mean Time Since 
Diagnosis (years) 
2.7 ± 0.9* 7.3 ± 2.4+ - 
Diabetes 6 (9.7) 3 (14) 0 (0) 
Beta-Blocker 22 (35.5) 0 (0) 0 (0) 
ACEI/ARB 31 (50) 15 (68) 0 (0) 
Statin 36 (58.1) 10 (46) 0 (0) 
CCB 21 (33.9) 12 (55) 0 (0) 
Loop Diuretic 30 (48.4) 8 (36) 0 (0) 
Median BNP 52.1 (17-87)* 11.9 (1-23) 28.8 (8-40) 
Hemoglobin (g/L) 137.1 ± 11.6 142.3 ± 9.3 140.5 ± 10.2 
Creatinine (μmol/L) 79.5 ± 24.6 77.1 ± 13.9 75.8 ± 11.3 
Rest Heart Rate (bpm) 79.4 ± 18.9 78.4 ± 14.1 70.8 ± 11.1 
Rest SBP (mmHg) 146.6 ± 23.7+ 147.2 ± 7.2+ 135.4 ± 16.0 
Rest DBP (mmHg) 82.1 ± 12.4 82.0 ± 12.0 81.6 ± 12.1 
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Peak Heart Rate (bpm) 125.9 ± 25.0* 158.6 ± 13.7 149.6 ± 12.6 
Peak SBP (mmHg) 170.5 ± 28.2 190.7 ± 18.7+ 167.1 ± 27.0 
Peak DBP (mmHg) 77.0 ± 15.2 88.1 ± 30.3 85.8 ± 12.3 
Peak VO2 12.6 ± 3.5* 27.0 ± 5.9 31.4 ± 7.5 
VE/VCO2 40.4 ± 6.3* 28.2 ± 2.7 27.6 ± 5.3 
BMI – body mass index; ACEI – angiotensin converting enzyme inhibitor; ARB – 
angiotensin II receptor blocker; CCB – calcium channel blocker; BNP – B-type 
natriuretic peptide; SBP – systolic blood pressure; DBP – diastolic blood pressure 
* p<0.05 vs. controls and hypertensive patients; + p<0.05 vs. controls  
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Table 2. Echocardiographic Data 
 HFpEF (n=62) Hypertensives 
(n=22) 
Controls 
(n=28) 
p value 
LVEF (%) 65.1 ± 8.2 65.4 ± 8.4 64.2 ± 6.4 0.85 
E 0.74 ± 0.25 0.72 ± 0.21 0.75 ± 0.16 0.89 
A 0.90 ± 0.24 0.83 ± 0.16 0.80 ± 0.18 0.07 
E/A 0.85 ± 0.24 0.86 ± 0.18 0.98 ± 0.27 0.06 
E’ (septal) 6.3 ± 1.8 6.8 ± 1.8 7.6 ± 1.8* 0.007 
E’ (lateral) 9.5 ± 2.7 8.4 ± 2.9 10.2 ± 2.7 0.76 
E/E’ (septal) 12.65 ± 5.64 11.29 ± 4.34 10.40 ± 3.21 0.12 
E/E’ (lateral) 9.60 ± 3.82 9.40 ± 3.58 7.71 ± 1.90 0.06 
E/E’ (average) 11.12 ± 4.41 10.34 ± 3.20 9.04 ± 2.06 0.07 
Number of 
patients E/E’ ≥13 
17 (27.4) 6 (27.3) 2 (7.7) 0.11 
Estimated PASP 30.0 ± 4.5 27.3 ± 4.7 25.6 ± 4.2 0.12 
eGCS -12.74 ± 3.50 -14.03 ± 4.26 -18.08 ± 2.61*+ <0.001 
eGLS -16.05 ± 2.16+ -18.58 ± 2.84* -19.59 ± 1.49* <0.001 
GCS Rate -0.95 ± 0.26 -0.73 ± 0.57 -1.05 ± 0.18+ 0.023 
GLS Rate  -0.87 ± 0.17 -0.99 ± 0.18 -0.93 ± 0.16 0.13 
LV Torsion 13.39 ± 6.00 13.52 ± 5.41 22.86 ± 4.88*+ <0.001 
LVEF – left ventricular ejection fraction; PASP – pulmonary artery systolic pressure; 
eGCS – echocardiographic global circumferential strain; eGLS – echocardiographic 
global longitudinal strain 
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*p<0.05 vs HFpEF patients; +p<0.05 vs hypertensives 
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Table 3. CMR Data 
 HFpEF 
(n=62) 
Hypertensives 
(n=22) 
Controls 
(n=28) 
p value 
LVEF (%) 66.7 ± 9.3 65.6 ± 6.7 64.3 ± 4.3 0.42 
LVEDVi 67.8 ± 17.5 64.8 ± 11.7 60.6 ± 23.3 0.06 
LVESVi 23.2 ± 12.1 17.5 ± 7.7 23.1 ± 11.9 0.82 
LVMi 70.8 ± 20.2+ 107.2 ± 23.1* 69.2 ± 23.2+ <0.001 
cGCS (%) -15.10 ± 
2.62 
-16.23 ± 3.81 -18.50 ± 1.21* 0.045 
Native T1 (ms) 1218 ± 78 1185 ± 58. 1194 ± 29 0.06 
ECV (%) 35.9 ± 5.0+ 31.9 ± 5.2* 27.0 ± 4.3*+ <0.001 
LVEF – left ventricular ejection fraction; LVEDVi – indexed left ventricular end-diastolic 
volume; LVESVi – indexed left ventricular end-systolic volume; LVMo – indexed left 
ventricular mass; cGCS – CMR global circumferential strain; ECV – extracellular volume 
*p<0.05 vs HFpEF patients; +p<0.05 vs hypertensives 
 
